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data for renal function-related traits in 7699 Japanese sub-
jects were examined in a replication study. Among the 
five SNVs, rs55975541 in CDC42BPG was significantly 
(P < 4.90 × 10− 4) related to the serum concentration of uric 
acid in the replication cohort. We also examined the SNVs 
detected in our longitudinal EWASs with the information 
on P values in GKDGEN meta-analysis data. Four SNVs in 
SLC15A2 were significantly associated with the estimated 
glomerular filtration rate in European ancestry populations, 
although these SNVs were related to the serum concentra-
tion of uric acid with borderline significance in our longitu-
dinal EWASs. Our findings indicate that CDC42BPG may 
be a novel susceptibility locus for hyperuricemia.
Keywords Chronic kidney disease · Creatinine · 
Estimated glomerular filtration rate · Generalized 
estimating equation · Hyperuricemia · Uric acid
Abstract Chronic kidney disease and hyperuricemia 
are serious global health problems. Recent genome-wide 
association studies have identified various genetic variants 
related to these disorders. However, most studies have been 
conducted in a cross-sectional manner. To identify novel 
susceptibility loci for chronic kidney disease or hyperurice-
mia, we performed longitudinal exome-wide association 
studies (EWASs), using ~ 244,000 genetic variants and 
clinical data of Japanese individuals who had undergone 
annual health checkups for several years. After establishing 
quality controls, the association of renal function-related 
traits in 5648 subjects (excluding patients with dialysis 
and population outliers) with 24,579 single nucleotide 
variants (SNVs) for three genetic models (P < 3.39 × 10− 7) 
was tested using generalized estimating equation mod-
els. The longitudinal EWASs revealed novel relations of 
five SNVs to renal function-related traits. Cross-sectional 
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Introduction
Chronic kidney disease (CKD) and hyperuricemia are 
caused by renal function abnormalities and are multifacto-
rial disorders resulting from interactions between genetic 
background and environmental factors. The goal of the 
present study was to identify novel susceptibility loci for 
CKD or hyperuricemia in Japanese individuals. CKD is a 
global health problem and an independent risk factor for 
cardiovascular diseases (Schiffrin et al. 2007; Hill et al. 
2016; Webster et al. 2017). Recent genome-wide association 
studies (GWASs) have identified various genetic variants 
that confer susceptibility to CKD-related traits. A previous 
GWAS examined relations between genetic variants and the 
prevalence of CKD or estimated glomerular filtration rate 
(eGFR), based on serum creatinine and cystatin C levels in 
four population-based cohorts with European ancestry, and 
identified several genetic loci related to any of the clinical 
parameters examined (Köttgen et al. 2009). Several GWASs 
consistently identified a genetic variant at rs12917707 in 
the UMOD gene as a CKD susceptibility locus (Chambers 
et al. 2010; Böger et al. 2011; Pattaro et al. 2016). However, 
a recent GWAS for Icelanders did not detect this association 
(Sveinbjornsson et al. 2014). A meta-analysis of GWASs 
for 71,149 East Asian individuals, including those in an 
in silico replication study, identified another genetic vari-
ant, rs11864909, in UMOD and the linkage disequilibrium 
(LD) with rs12917707 was not strong (r2 = 0.02), although 
rs12917707 was excluded from the GWAS meta-analysis 
because of low minor allele frequency (MAF < 0.01) (Okada 
et al. 2012). This analysis showed that 32 loci were sig-
nificantly associated with four kidney function-related traits 
(blood urea nitrogen, serum creatinine, eGFRcrea, and uric 
acid).
Hyperuricemia is an important risk factor for gout (Lioté 
2003). Overproduction of uric acid or decreased renal uric 
acid excretion may cause this disorder. Two meta-analyses of 
GWASs for population-based cohorts with European ances-
try commonly identified relations between serum concentra-
tions of uric acid and single nucleotide variants (SNVs) in 
six loci (ABCG2, GCKR, PDZK1, SLC2A9, SLC17A1, and 
SLC22A11) (Kolz et al. 2009; Yang et al. 2010). In previous 
studies, several solute carrier family (SLC) genes showed 
associations with hyperuricemia or gout in diverse ethnic 
groups (Matsuo et al. 2008; Köttgen et al. 2013; Phipps-
Green et al. 2016; Nakayama et al. 2017). However, allele 
frequencies of SNVs associated with serum concentrations 
of uric acid varied across different ethnic groups (Köttgen 
et al. 2013). Therefore, disease-associated SNVs are dif-
ferent between ethnic groups owing to genetic background 
differences.
Extensive large-scale GWASs for renal function-related 
traits have been conducted focusing on populations with 
European ancestry. Therefore, it is possible that genetic rela-
tions in non-European populations have not been defini-
tively defined. Conventional GWASs have been conducted 
in a cross-sectional manner that measures traits at a single 
point in time. In the present study, we traced longitudinal 
changes of anthropometric and clinical data in 5648 Japa-
nese individuals who had undergone annual health checkups 
for several years. On the basis of these data, we performed 
longitudinal exome-wide association studies (EWASs) with 
the use of exome-array-based genotyping methods to explore 
novel susceptibility loci for CKD or hyperuricemia in the 
Japanese cohort.
Methods
Study subjects
A total of 5648 community-dwelling individuals were 
recruited from those who visited the Health Care Center of 
Inabe General Hospital (Inabe, Mie, Japan) for an annual 
health check-up from April 2003 to March 2014. All partici-
pants had each undergone 1–11 medical examinations, and 
the average follow-up period was 5 years. We refer to this 
cohort as the “discovery cohort.” Methods for the collec-
tion and storage of medical examination data and genomic 
DNA samples have been described previously (Yamada et al. 
2015). Cross-sectional data for CKD- and hyperuricemia-
related traits in 7699 Japanese subjects (Gifu Prefectural 
Tajimi Hospital, Tajimi; Gifu Prefectural General Medical 
Center, Gifu; Japanese Red Cross Nagoya First Hospital, 
Nagoya; Hirosaki University Hospital and Hirosaki Stroke 
Center, Hirosaki, Japan) were used for replication studies of 
candidate SNVs identified from our longitudinal EWASs. 
We refer to this cohort as the “replication cohort”.
Glomerular filtration rate was estimated with the use of 
the simplified prediction equation derived from the modi-
fied version of that described in the Modification of Diet 
in Renal Disease (MDRD) Study, as proposed by the Japa-
nese Society of Nephrology (Zhang et al. 2017): eGFR 
(mL  min− 1 1.73 m− 2) = 194 × [age (years)]−0.287 × [serum 
creatinine (mg/dL)]−1.094 × [0.739 if female]. The National 
Kidney Foundation-Kidney Disease Outcomes Quality Ini-
tiative guidelines recommend a diagnosis of CKD if eGFR is 
< 60 mL  min− 1 1.73 m− 2 (Go et al. 2004). We thus adopted 
the criterion of an eGFR of < 60 mL  min− 1 1.73 m− 2 (actual 
range 12.2 to 59.9 mL  min− 1 1.73 m− 2) for the diagnosis of 
CKD. The control individuals for the EWAS of CKD had 
an eGFR of ≥ 90 mL  min− 1 1.73 m− 2 (actual range 90.1 to 
595.5 mL  min− 1 1.73 m− 2) and did not appear to have func-
tional or structural abnormalities of the kidneys or a history 
of renal disease. Subjects with hemodialysis or peritoneal 
dialysis were excluded from the study.
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Hyperuricemia was defined by the serum uric acid con-
centration of > 7.0 mg/dL (> 416 µmol/L, actual range, 
416.4 to 814.9 µmol/L), as proposed by the Japanese Soci-
ety of Gout and Nucleic Acid Metabolism (Japanese Society 
of Gout and Nucleic Acid Metabolism 2012), or the taking 
of uric acid-lowering medication. Individuals taking drugs 
that may cause secondary hyperuricemia were excluded. The 
control individuals for the EWAS of hyperuricemia had a 
serum uric acid concentration of ≤ 416 µmol/L (actual range, 
29.7 to 410.4 µmol/L) and had no history of hyperuricemia, 
gout, or uric acid-lowering medication.
The distributions of eGFR and serum concentrations of 
creatinine and uric acid are shown in Fig. 1. In the longi-
tudinal EWASs for eGFR or the serum concentration of 
creatinine, a total of 5636 subjects were examined (a total 
of 25,371 examinations). A total of 5487 subjects were 
examined in the EWAS for the serum concentration of uric 
acid (a total of 24,873 examinations). In the EWASs for the 
prevalence of CKD or hyperuricemia, 1646 individuals (606 
subjects with CKD and 1040 controls; a total of 7583 exami-
nations) or 5487 individuals (847 subjects with hyperurice-
mia and 4640 controls; a total of 24,873 examinations) were 
examined, respectively. The replication cohort involved 2517 
subjects with CKD and 885 controls in the study for CKD, 
or 972 subjects with hyperuricemia and 4584 controls in the 
study for hyperuricemia.
Longitudinal EWAS
A longitudinal EWAS for the discovery cohort was per-
formed based on ~ 244,000 genetic variants and longitu-
dinal data of medical examinations. Infinium HumanEx-
ome-12 ver 1.2 BeadChip and Infinium Exome-24 ver 1.0 
BeadChip (Illumina, San Diego, CA, USA) were used for 
genotyping subjects in the discovery cohort. These arrays 
include putative functional exonic variants selected from 
> 12,000 individual exome and whole-genome sequences 
across diverse ethnic populations (Grove et al. 2013). We 
performed quality controls and discarded the following 
SNVs: (1) monomorphic sites, (2) SNVs with MAF of 
< 0.05, (3) SNVs in which the genotype distribution sig-
nificantly deviated from Hardy–Weinberg equilibrium 
(P < 0.001) in controls, and (4) SNVs located on mitochon-
drial DNA or sex chromosomes. Among Inabe subjects, 
four were identified as population outliers by principal 
component analysis (PCA) of SNVs, using the EIGEN-
STRAT method (Price et al. 2006) via JMP Genomics 
version 6.0 (SAS Institute, Cary, NC, USA) to detect pop-
ulation stratification on a genome-wide scale. The four 
outliers were removed from our longitudinal EWAS.
Next, we converted the genotyping data of the subjects 
into numeric data with dominant, additive, and recessive 
models, resulting in 24,579 SNVs. The dominant and 
recessive models were defined as “0, AA; 1, AB + BB” and 
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Fig. 1  Count distributions for longitudinal data of serum concentration of creatinine (a), eGFR (b), and serum concentration of uric acid (c) in 
the discovery cohort. eGFR estimated glomerular filtration rate
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“0, AA + AB; 1, BB” (A, major allele; B, minor allele), 
respectively, whereas the additive model was defined as 
“0, AA; 1, AB; 2, BB”. Quantile–quantile plots for the 
P values in the three genetic models are shown in Online 
Resources 1–3. The genomic inflation factor (λ) of P val-
ues ranged from 1.05 to 1.21.
Statistical analyses
To examine associations between SNVs and longitudinal 
changes in CKD-related traits (the prevalence of CKD, 
eGFR, and serum concentration of creatinine), we used the 
generalized estimating equation (GEE) model (Liang and 
Zeger 1986; Hanley et al. 2003) with adjustments for age, 
gender, and the prevalence of hypertension and type 2 dia-
betes mellitus using the R package ‘geepack’ (Halekoh et al. 
2006). In longitudinal EWASs for hyperuricemia-related 
traits (the prevalence of hyperuricemia and serum concen-
tration of uric acid), the association with genetic variants 
was tested using the GEE model with adjustments for age 
and gender. The wave argument was used to specify the 
ordering of repeated measurements within individuals. The 
statistical significance of the association was P < 3.39 × 10− 7 
(0.05/24,579 SNVs × 6) for each genetic model, after Bon-
ferroni’s correction to compensate for multiple comparisons 
of genotypes with the clinical parameters. Sitlani et al. (Sit-
lani et al. 2015) reported that a small effective sample size 
can increase the chances of generating type I errors. They 
recommended the use of ‘approxdf’, a scale of small effec-
tive sample size, and an approxdf of ≥ 10 could reduce type 
I errors. Therefore, we estimated the approxdf by the R pack-
age ‘bosswithdf’ (Voorman et al. 2012; Sitlani et al. 2015). 
To solve the issue of association with small effective sam-
ple sizes, we set to strict approxdf threshold, and discarded 
SNVs with approxdf of < 30.
The association of candidate SNVs identified from our 
longitudinal EWASs was tested in the replication cohort 
using the Chi-square test (for categorical data) or linear 
regression analysis (for quantitative data). In addition, we 
also examined relations of the candidate SNVs identified, 
using information on P values in datasets of four meta-anal-
ysis studies (Köttgen et al. 2010; Pattaro et al. 2016; Gorski 
et al. 2017; Li et al. 2017) from GKDGEN meta-analysis 
data which are publicly available (https://www.nhlbi.nih.
gov/research/intramural/researchers/ckdgen).
Estimates of linkage disequilibrium
We estimated the LD among SNVs, using Haploview ver-
sion 4.2 program (Barrett et al. 2005). In addition, we sur-
veyed the LD between a candidate SNV detected from our 
longitudinal EWASs and other SNVs that were not included 
in the exome arrays used, employing LDlink web-based tools 
[https://analysistools.nci.nih.gov/LDlink/, (Machiela and 
Chanock 2015)]. The regulatory potential of each SNV was 
based on RegulomeDB scores [http://www.regulomedb.org/, 
(Boyle et al. 2012)]. Relations of candidate SNVs to disor-
ders reported in previous studies were investigated using 
DisGeNET [http://www.disgenet.org/web/DisGeNET/, 
(Piñero et al. 2015)], GWAS Catalogue [https://www.ebi.
ac.uk/gwas/, (MacArthur et al. 2017)], and GWAS Central 
[http://www.gwascentral.org/, (Beck et al. 2014)] databases.
Results
Characteristics of subjects in the discovery cohort
Characteristics of 5648 subjects in the discovery cohort, 
including 606 subjects with CKD and 1040 controls, and 
847 subjects with hyperuricemia and 4640 controls, are 
shown in Table 1. The prevalence of both CKD and hyper-
uricemia was higher in males than in females; the proportion 
of males was 64.7% in subjects with CKD and 94.3% in 
subjects with hyperuricemia. The prevalence of hyperten-
sion, type 2 diabetes mellitus, and dyslipidemia was higher 
in patients with CKD or hyperuricemia than in correspond-
ing controls. Weight, body mass index, waist circumference, 
systolic and diastolic blood pressures, fasting plasma glu-
cose, blood hemoglobin  A1c, and serum concentrations of 
triglycerides, low-density lipoprotein cholesterol, creatinine, 
and uric acid, but not height or eGFR, were also greater in 
patients with CKD or hyperuricemia than in corresponding 
controls.
SNVs associated with CKD and hyperuricemia 
in longitudinal EWASs
The GEE model with adjustments for age, gender, and the 
prevalence of hypertension and type 2 diabetes mellitus in 
the dominant and additive models showed significant rela-
tions (P < 3.39 × 10− 7) of rs11543349 in OGFR to serum 
creatinine concentration and eGFR (Table 2 and Online 
Resource 4). Approxdf values were 262 and 71 in the 
dominant and additive models, respectively. The associa-
tion of rs11543349 with the serum concentration of creati-
nine showed the significance level with P = 1.2 × 10− 8 and 
2.7 × 10− 8 in dominant and additive models, respectively. 
According to DisGeNET, GWAS Catalogue, and GWAS 
Central databases, the relation of this SNV to renal function 
has not been reported.
The GEE model with adjustments for age and gender 
showed that 16 SNVs were significantly (P < 3.39 × 10− 7) 
associated with the prevalence of hyperuricemia or serum 
concentration of uric acid in the three genetic models, 
and their approxdf values were > 30 (Online Resource 
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4). Of these SNVs, nine are located at seven gene loci 
(DDX39B, NFKBIL1, CDC42BPG, CDC63, BRAP, 
ACAD10, and PCNX3) that might be novel susceptibility 
loci for hyperuricemia. However, five candidate SNVs at 
12q24.1 exhibited moderate or strong LD (0.43 ≤ r2 ≤ 0.99) 
with rs671 of ALDH2 that has been reported to be associ-
ated with renal function-related traits (Levey et al. 2005; 
Sakiyama et al. 2016, 2017) (Online Resource 5). Thus, 
we did not consider the candidate SNVs at 12q24.1 as 
novel susceptibility loci for hyperuricemia. It has been 
reported that rs505802 of SLC22A12 and rs504915 of 
NRXN2 are related to the serum concentration of uric 
acid (Kolz et al. 2009; Okada et al. 2012). These SNVs 
are located relatively close (~ 240 kb) to rs55975541 of 
CDC42BPG at 11q13.1. However, these SNVs were not in 
LD (rs505802, r2 = 0.06, Dʹ = 0.26; rs504915, r2 = 0.10, D′ 
= 0.39) (Fig. 2). Therefore, it is possible that rs55975541 
of CDC42BPG independently affects the serum concen-
tration of uric acid. Consequently, four genes (DDX39B, 
NFKBIL1, CDC42BPG, and PCNX3) were identified 
as candidates for novel susceptibility loci that might be 
related to the serum concentration of uric acid. Of these 
candidates, the association of rs55975541 in CDC42BPG 
showed the significance level with P = 3.7 × 10− 12 in the 
dominant model (Online Resource 4).
Replication studies for candidate SNVs related to CKD 
or hyperuricemia
We examined the relation of 17 candidate SNVs identified 
from our longitudinal EWASs to CKD or hyperuricemia 
using the Chi-square test or linear regression analysis, using 
cross-sectional data for CKD and hyperuricemia-related 
traits in 7699 Japanese subjects of the replication cohort 
(Online Resource 6). In this replication study, rs55975541 
in CDC42BPG was significantly [P < 4.90 × 10− 4 (0.05/17 
SNVs × 6)] related to the serum concentration of uric acid. 
We also assessed relations of the candidate SNVs detected 
in the discovery cohort with CKD or hyperuricemia, using 
GKDGEN meta-analysis data on European or African ances-
try populations (Online Resource 7). The in silico replica-
tion study did not show significant association with the five 
candidate SNVs that were newly identified in the discov-
ery cohort. However, four SNVs (rs2049330, rs2257212, 
Table 1  Characteristics of study subjects in the discovery cohort without dialysis patients or population outliers identified by the PCA method
CAD coronary artery disease, MI myocardial infarction, CI cerebral infarction, HDL high-density lipoprotein, LDL low-density lipoprotein, 
eGFR estimated glomerular filtration rate
a Values in parentheses indicate the numbers of measurements taken. Quantitative data are means and standard error
b The numbers are based on data examined in the latest year
Characteristic Controla CKDa Controla Hyperuricemiaa
No. of  subjectsb 1040 606 4640 847
Sex (male/female, %)b 50.4/49.6 64.7/35.3 49.4/50.6 94.3/5.7
Age (years) 46.6 ± 0.14 (5608) 64.4 ± 0.21 (1975) 53.2 ± 0.08 (20,775) 52.1 ± 0.18 (4103)
Height (cm) 162.8 ± 0.12 (5581) 161.2 ± 0.21 (1923) 161.5 ± 0.06 (20,686) 168.6 ± 0.11 (4064)
Weight (kg) 60.7 ± 0.17 (5581) 61.7 ± 0.27 (1923) 59.6 ± 0.08 (20,686) 69.9 ± 0.19 (4064)
Body mass index (kg/m2) 22.8 ± 0.05 (5581) 23.6 ± 0.07 (1923) 22.7 ± 0.02 (20,686) 24.5 ± 0.06 (4064)
Waist circumference (cm) 80.2 ± 0.15 (4130) 83.1 ± 0.24 (1446) 80.0 ± 0.07 (16,140) 85.6 ± 0.16 (3182)
Smoking (%) 41.4 (5608) 33.0 (1975) 35.2 (20,775) 65.8 (4103)
Hypertension (%) 23.3 (5608) 63.5 (1975) 31.4 (20,775) 48.2 (4103)
Systolic blood pressure (mmHg) 118.0 ± 0.21 (5581) 126.2 ± 0.38 (1921) 119.8 ± 0.11 (20,684) 125.2 ± 0.25 (4062)
Diastolic blood pressure (mmHg) 73.1 ± 0.16 (5581) 77.0 ± 0.28 (1921) 73.9 ± 0.08 (20,684) 80.2 ± 0.19 (4062)
Type 2 diabetes mellitus (%) 10.5 (5608) 21.5 (1975) 11.6 (20,775) 12.5 (4103)
Fasting plasma glucose (mmol/L) 5.62 ± 0.018 (5601) 5.78 ± 0.028 (1957) 5.57 ± 0.008 (20,750) 5.74 ± 0.015 (4094)
Blood hemoglobin  A1c (%) 5.65 ± 0.012 (4000) 5.88 ± 0.015 (1711) 5.70 ± 0.005 (16,245) 5.72 ± 0.010 (2854)
Dyslipidemia (%) 49.4 (5608) 73.7 (1975) 57.5 (20,775) 74.7 (4103)
Serum triglycerides (mmol/L) 1.23 ± 0.015 (5599) 1.40 ± 0.020 (1967) 1.18 ± 0.005 (20,760) 1.73 ± 0.020 (4100)
Serum HDL-cholesterol (mmol/L) 1.62 ± 0.006 (5598) 1.52 ± 0.010 (1963) 1.65 ± 0.003 (20,757) 1.44 ± 0.006 (4098)
Serum LDL-cholesterol (mmol/L) 3.05 ± 0.011 (5393) 3.17 ± 0.018 (1854) 3.18 ± 0.005 (20,040) 3.28 ± 0.013 (3938)
Serum creatinine (µmol/L) 52.7 ± 0.12 (5608) 92.2 ± 0.58 (1975) 63.2 ± 0.10 (20,701) 78.2 ± 0.28 (4085)
eGFR (mL  min− 1 1.73− 1  m− 2) 100.7 ± 0.16 (5608) 52.9 ± 0.17 (1975) 80.6 ± 0.11 (20,701) 74.3 ± 0.24 (4085)
Serum uric acid (µmol/L) 303.5 ± 1.11 (5448) 374.7 ± 1.99 (1926) 300.7 ± 0.44 (20,775) 462.7 ± 0.70 (4103)
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rs1143671, and rs1143672) in SLC15A2 were significantly 
(P < 4.90 × 10− 4) associated with eGFR in European ances-
try populations, although these SNVs were related to the 
serum concentration of uric acid with borderline significance 
(P = 5.50 × 10− 7 to 6.40 × 10− 7) in our longitudinal EWASs.
Survey of LD with disease‑associated SNVs that were 
not examined in the longitudinal EWAS
We further investigated whether the allele frequency of the 
replicated target SNV in CDC42BPG was affected by other 
previously reported SNVs that were not included in the 
exome arrays used and which exhibited strong LD. LDproxy, 
an LDlink application, indicated rs55975541 in CDC42BPG 
was in LD (r2 ≥ 0.8, P < 0.0001) with rs80094634 only in 
JPT (Japanese in Tokyo, Japan) from the 1000 Genomes 
Project database [http://www.internationalgenome.org, (The 
1000 Genomes Project Consortium 2010)] (Online Resource 
8). The nucleotide substitution at the non-genotyped SNV 
was silent (intronic variant), whereas the variant at the can-
didate SNV of CDC42BPG can alter an amino acid (non-
synonymous substitution). According to the Ensembl human 
database (http://www.ensembl.org/Homo_sapiens/), it is 
possible that the nonsynonymous substitution has an effect 
on the protein function because the amino acid substitu-
tion was predicted to be “probably damaging” with scores 
of zero by SIFT prediction and 0.998 by PolyPhen analy-
sis. Therefore, rs55975541 is more likely to be related to 
hyperuricemia than, the non-genotyped SNV, rs80094634. 
The LDproxy analysis also showed that rs55975541 in 
CDC42BPG was not in LD with any genetic variants in the 
established SLC22A11, SLC22A12, and NRXN2 loci (Online 
Resource 8).
Relation of previously reported SNVs to renal 
function‑related traits in longitudinal EWASs 
for the discovery cohort
We comprehensively assessed significance levels of 291 
SNVs at 55 previously known CKD- or hyperuricemia-
associated loci (Online Resource 9). Of the SNVs examined, 
103 at 37 loci, including ABCG2, GCKR, and UMOD, were 
significantly (P < 3.39 × 10− 7) associated with renal func-
tion-related traits in any of the three genetic models. In the 
discovery cohort, MAFs of some previously reported SNVs 
were less than 5%. For instance, the SNV rs121907892 of 
SLC22A12 was significantly associated with the prevalence 
of hyperuricemia and serum concentration of uric acid in all 
the genetic models (P < 2.0 × 10− 16). However, rs121907892 
was excluded from our longitudinal EWAS because of low 
minor allele frequency (MAF < 0.03). The differences in 
significance levels between the present and previous stud-
ies might be due to sample sizes, statistical methods, or 
differences in genetic background among the populations 
examined.
Discussion
In the present study, 17 SNVs showed significant relations 
with CKD- or hyperuricemia-related traits. Five of these 
Fig. 2  Linkage disequilibrium 
(LD) of 12 biallelic sites across 
approximately 475 kb genomic 
region at 11q13.1 using single 
nucleotide variations (SNVs) 
data used in the present study. 
The diagram was depicted by 
the Haploview version 4.2. 
The SNVs with the minor 
allele frequency of < 0.01 were 
removed from the analysis. The 
hyperuricemia-associated SNVs 
(rs505802 of SLC22A12 and 
rs55975541 of CDC42BPG) 
identified by the generalized 
estimating equation model are 
shown in bold
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SNVs have not been reported in previous studies. How-
ever, the relation of these SNVs to CKD or hyperurice-
mia could not be found in the replication study, except 
for rs55975541 in CDC42BPG. In the longitudinal EWAS 
for the discovery cohort, the SNV in CDC42BPG was 
significantly (P = 3.7 × 10− 12) associated with the serum 
concentration of uric acid. The association of rs55975541 
was determined using cross-sectional data for the serum 
concentration of uric acid of 7699 Japanese subjects in 
the replication cohort. The LDproxy analysis suggests 
that this SNV independently affects the incidence of 
hyperuricemia.
MRCKγ encoded by CDC42BPG is ubiquitously 
expressed in a variety of tissues and organs including 
the kidney, according to The Human Protein Atlas data-
base (http://www.proteinatlas.org/). This protein may act 
as a downstream effector of CDC42 in the regulation of 
cytoskeletal reorganization (Ng et al. 2004). The kidney-
specific Cdc42 knockout mice exhibited early postnatal 
death due to renal failure (Choi et al. 2013). The nucleo-
tide substitution at rs55975541 in CDC42BPG alters an 
amino acid residue at position 1237 (Arg1237Trp). The 
amino acid change may have an effect on the protein 
function, as predicted by SIFT and PolyPhen. Although 
CDC42BPG may be a susceptibility locus for renal func-
tion, the functional relevance of the candidate SNV to the 
serum concentration of uric acid remains unclear.
Despite many studies of associations between several 
SLC genes and hyperuricemia-related traits in diverse 
ethnic groups (Matsuo et al. 2008; Köttgen et al. 2013; 
Phipps-Green et al. 2016; Nakayama et al. 2017), asso-
ciation with SLC15A2 has not been reported, according 
to the public databases. It is noteworthy that three non-
synonymous substitutions (at rs2257212, rs1143671, and 
rs1143672) in SLC15A2 were significantly associated with 
eGFR in European ancestry populations from GKDGEN 
meta-analysis data, whereas these SNVs were related to 
the serum concentration of uric acid with a borderline sig-
nificance in our longitudinal EWASs.
There were some limitations to the present study. First, 
the longitudinal EWAS was conducted in a local Japanese 
population only. Although we examined relations of can-
didate SNVs to CKD- or hyperuricemia-related traits in 
the replication studies, these studies were conducted in a 
cross-sectional manner. Therefore, replication of longitu-
dinal EWASs in other Japanese populations or other ethnic 
groups is required to verify the relations of the identi-
fied SNVs to the relevant diseases. Second, the functional 
relevance of the candidate SNV to the pathogenesis of 
the diseases examined remains unclear. Therefore, further 
functional analysis is required to clarify the results of this 
study.
In conclusion, our findings indicated that rs55975541 in 
CDC42BPG was significantly associated with the serum 
concentration of uric acid in our EWASs. Genotyping for the 
SNV detected in our longitudinal EWAS may be informative 
for assessment of genetic risk for hyperuricemia.
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